Study Focus: Weaning Gut MicrobiotaMilkomeNCT07026526
Human Milk Oligosaccharides' Impact on Maturation of the Gut Microbiota
An observational study of Study Focus: Weaning Gut Microbiota, run by Technical University of Denmark at 1 site in Denmark.
Trial summary
Human milk oligosaccharides (HMOs) are the third largest component of human milk after fat and milk sugar (lactose). HMOs play an important role in selecting the gut microbiota (GM) in newborn breastfed infants. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Study Focus: Weaning Gut Microbiota
- How many people
- 18 participants
- Where
- 1 siteDenmark
- Study dates
- 17 Aug 2022to 29 Jan 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Residents of the greater Copenhagen area, Denmark.
Who may be able to join
- 1. Mothers
- Age 18 years or older
- Non-smoker
- Residents of the greater Copenhagen area
- Danish or English speaking
- No history of gestational diabetes during pregnancy (received standard care from midwife)
Show all 12Show fewer
- Pre-pregnancy body mass index between 20-30 kg/m2
- Categorised as low risk pregnancy
- Had a vaginal full-term delivery (gestational age ≥37 weeks)
- Planned to exclusively breastfeed until non-breast milk diet (solid food) introduction
- For infants:
- No additional criteria than what is specified above for the mother
Who cannot join
- Mother Use of antibiotics after the 6th month of the last pregnancy
- Infant
- Admission to the neonatal or intensive care unit
- Use of antibiotic since birth or thereafter
- Infant formula feeding during the study
Trial locations and contacts
1 site in 1 country.
Denmark1 site
Department of Neonatal and Pediatric Intensive Care Copenhagen University Hospital, Rigshospitalet
Copenhagen, 2100
About this study
Human milk oligosaccharides (HMOs) are the third largest component of human milk after fat and milk sugar (lactose). HMOs play an important role in selecting the gut microbiota (GM) in newborn breastfed infants. However, the mechanisms underpinning the maturation process that the gut microbiota undergoes during the transition from a breast milk to a solid food diet (weaning) and the impact of HMOs on this transition remain unknown.
The aim of the present study:
Read more
- Evaluate the contribution of HMOs to the maturation of the GM during weaning
- Analyze the utilization of HMOs and other complex carbohydrates from diet and from the human host by the GM during the weaning period
We have recruited a cohort of healthy volunteer mothers and their infants (n=9 pairs, two were disqualified and 7 pairs were included in the final analyses). After oral and written informed consent, we collected stool samples from the mother-infant dyads at three time points: 1) just before the introduction of solid food (weaning start), 2) At a time point corresponding to 70% of the infant's meals being breast milk and 30% being toddler food within a 24-hour period (early weaning), and 3) late weaning, defined as the time point corresponding to approx. 30% and 70% of an infant's meals are breast milk and solid food, respectively, within a 24-hour period (late weaning).
The samples have been collected and stored in a Pseudoanonymous Research Bank at the Technical University of Denmark until the data have been analyzed and published, except for participants who allow storage indefinitely through a separate written consent form. In this case, excess material left over after the experiment will be transferred to a Pseudoanonymous Biobank for future research.
The stool samples have been analyzed for gut microbiota composition and carbohydrate utilization potential (based on whole metagenome sequencing). The fecal samples were also enriched on different carbohydrate sources and the enriched consortia were sequenced and analyzed as above. Strains were also isolated from both mother and infant samples via growth on a variety of carbohydrate sources. The genome analyses were performed exclusively on bacteria and human DNA was excluded.
In addition, selected fecal samples were used to colonize germfree mice and the mice were fed with alternating customized mother's milk-like and dietary fiber-rich diets. Similar metagenome analyses were performed on selected fecal samples from this mouse intervention study.
Read the detailed description
Recruitment of study cohort and informed consent The mother-infants pair cohort have been recruited by Assoc. Prof. Lise Aunsholt (Copenhagen University Hospital, Rigshospitalet, Dept. Neonatology, Copenhagen, Denmark). We have advertised the study at the clinics of general practitioners in the Copenhagen area aiming to recruit pairs during the planned vaccination visit at an infant age of 3 month. Additionally, we have advertised the study via state employed health workers in conjunction with their standard visit at the mothers' residence 8 weeks after birth. The first contact with the subjects has been made either by the visiting nurses or the nurses of the general practitioner clinics.
Eligible participants were healthy mother-infant dyads, who met the inclusion criteria. Two enrolled pairs were disqualified due to intake of either formula or solid food during the study. Two mothers who had antibiotic at birth, otherwise fulfilled the inclusion criteria for both the mother and the infant, were enrolled towards the end of the study due to the low number of recruited volunteers. To assess eligibility, volunteers have answered a questionnaire provided in both English and Danish. For eligible volunteers, a personal meeting was arranged with the mothers and other accompanying persons (e.g. spouses or family members) to brief them on the study at Rigshospitalet Neonate Dept. The meeting was carried out by a nurse assigned by Assoc. Prof. Lise Aunsholt in a meeting room booked for this purpose at Rigshospitalet or online if that is more convenient for the volunteers. The assigned nurse provided oral information covering the purpose of the research, the scope of volunteer participation and general information regarding practicalities related to sample collection and sample handling. The nurse also reiterated the terms of participating in the study, especially its strictly voluntary nature and the rights to withdraw the consent to participate at any time without justification or consequences. The volunteers also got this information in a written form that includes the study purpose and background, the fate of their samples and the informed consent (available in Danish and English, provided as a separate participant information document) for signature. Additionally, the volunteers will also be informed on the possibility of signing separate consents to store their pseudonymized samples for potential future research.
A consideration time of 24-48 hours between the information meeting and the collection of the signed informed consents for both mothers and infants. After volunteers have given their consent, they were enrolled and provided with a study package containing written information regarding sample collection and handling, a feces collection kit, mother's milk collection tube, latex gloves and the study dairy. The stool and milk sample containers will be pre-labelled pseudonymously as to preclude traceability of samples to specific participants.
Sample collection and pseudonymization set-up The mothers were explicitly and thoroughly informed on the timing of the samples and were advised on how to estimate the timing for sample collection. The compliance of the mothers will be evaluated by including a table in the pseudonymous diary, where the mothers were asked to fill the numbers of breastmilk meals and the numbers of solid food means for the last ten meals prior to data collection.
Mothers in the enrolled infant-mother cohort were asked to collect stool and fill out the study diary at the time points indicated in the sampling scheme. The diary was also be pseudonymous to hinder traceability to specific donors. To ensure rapid collection and best quality samples, a person from the Technical University of Denmark (DTU), who is not affiliated with this study, was assigned sample pick-up from a collection site indicated by the mother subjects within the Copenhagen area. The sample collection containers will be pre-labelled with a QR code (generated at DTU) that encodes a letter identifier assigned to each mother-infant pair. In addition, the sample collection containers were pre-labelled with Arabic numerals (1, 2 or 3) to designate the sampling occasion as well as with the codes MF and IF, to designate mother's feces and infant feces, respectively.
Only the collaboration partner at Rigshospitalet and not the DTU team has access to the actual identities of the participants. By contrast, the Rigshospitalet partner did not have the code for the QR labels and will distribute the packages randomly, i.e. with no knowledge of which specific package is handed to which subject. After arrival of samples at DTU, the principle investigator Prof. Maher Abou Hachem will decode the samples and assign the samples to the one letter identifiers of individual mother-infant pairs before the PhD student (who is not involved in sample pick up) processes and handles the samples according to the single letter identifier. Thus, tracking a sample to a specific subject will be virtually impossible for participants in the project.
For the collection of fresh stool samples, participants were supplied and instructed to use a commercially available anaerobic stool collection kit (GutAlive or similar, see participant information document). The mothers will collect their samples after their first bowel movement of a day within the indicated time period. Thereafter mothers will collect their own milk sample and contact the research staff responsible for pick-up of their stool and milk samples. This will minimise the time between sample collection and processing.
Mothers also collected their infant feces from the first bowel movement of either the same day or at the closest occasion where this takes place. As soon as this sample is available, the mother's call for sample pick-up as described above. Until pick-up, mothers were asked to store the mother and infant stool samples in provided insulating cooler boxes.
Functional studies of the microbiota To investigate the potential role of HMOs in the maturation of the infant gut microbiota during weaning, standardized approaches to isolate bacteria from mother's milk and from the mother's/child's faeces, bacterial growth and competition assays, recombinant production and characterization of key proteins as well as analyses of bacterial metabolites of and genetic material (metagenomics and metatranscriptomic shotgun sequencing) will be carried out.
Statistic considerations The study is designed to investigate functional aspects of the microbiota and will focus on within-subject differences, whereby each individual serve as its own control. The number of subjects is within the budgetary constraints of the project and is designed to give the first snapshot into possible subject to subject variations in HMO responsive taxonomic groups and functional pathways.
Risks, side-effects and short and long-term effects The project does not involve any medical procedures on the subjects therefore no risks or other adverse effects are expected for participants.
Biological sample usage and storage The samples will be used for isolation of bacterial strains that are able to grow on HMOs and other complex glycans. Both DNA and RNA will be prepared from the samples and metagenome as well as metatranscriptome analyses will be performed for comparison of microbiota changes over the weaning period. A select of bacterial isolates will be sequenced and their carbohydrate fermentation products analysed.
The pseudonymously pre-labelled faecal material will be stored in a project pseudonymous research sample bank at DTU, Department of Biomedicine and Biotechnology under full compliance with the General Data Protection Regulation and the Danish Data Protection Act based on informed consent by the study volunteers. A data management plan of the project is already prepared for secure storage of data. Similarly, single strain isolates will be stored in a project strain and sample collection research sample bank. The aim of the default storage included in the informed consent is to address potential peer review requests when the study is sent for publications. The faecal and milk biosamples from the cohort will be stored until August 31st 2026 to insure that the material is available for the purposes of peer review requirement of the publications from the study, e.g. in case additional repeated experiments are needed. Thereafter any remaining biomaterial will be transferred to a biobank for future research for volunteers who have consented to this in a separate informed consent form.
Ethical aspects and handling of private data Samples will be pseudonymized and no personal data were accessible for analysis, which will render the data not traceable to a specific participant. The metagenomics and metatranscriptomic analyses will only include microbial DNA/RNA, i.e. Host genetic material information will be neither processed nor analysed.
Project economy The principal investigator Maher Abou Hachem has taken initiative to the study, which is funded by DFF | FNU. The funding provided salaries for a PhD and a postdoc that are employed full-time on the project as well as part-time technical laboratory assistant at DTU and operational costs at the PI's and co-applicants' laboratories. The Institution of the PI (DTU) administers the grant. The PI has no relationship to the funding council nor any other competing interests.
Study Participant compensation Participation in the study was on a voluntary basis and no compensation was offered. The study only involved taking fecal and did not involve any direct medical procedures on the participants. Therefore, no risk of damage was foreseen.
Dissemination of the study results The data as well as the positive, negative and inconclusive results from the study will be published in international peer reviewed journals, presented in scientific conferences and meetings and communicated through popular science fora and news outlets.
Scientific outcomes Insight from the study on the maturation of a healthy microbiota is important for future interventions to avoid the maturation of an aberrant gut community and the implications of this in terms of potential poor health trajectories.
Justification for the necessary involvement of subjects without legal capacity (infants) The aim of the research project is to understand how the maturation of the gut microbiota of infants is affected by human milk oligosaccharides from mothers' milk. Therefore, the research study was only meaningful on infants in the period just before weaning starts until the dietary transition to mostly solid food. The crucial involvement of infants in this specific nutritional phase was not possible to substitute by another target group. The healthy maturation of the gut microbiota of infants during the transition from mother's milk to solid food is critical for a life-long trajectory of health. The study only involves collection of faecal samples from the diapers and does not involve any direct procedure on the infants. Therefore, there are no foreseen risks, pain or any other discomfort incurred on the infant subjects. An informed consent will be collected and signed by both parents or legal guardians. The collaboration partner in Rigshospital Neonatology department, Assoc. Prof. Lise Aunshold is highly qualified and experienced in this type of clinical studies and she will arrange the information to the parents, as infants of this age are not within reach for information.
- Conditions
- Study Focus: Weaning Gut Microbiota
- Keywords
- Early life gut microbiome, Human milk oligosaccharides, mother's milk, weaning
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Mother-infant dyad | The gut microbiome of the cohort, consisting of mother-infant dyads will be analyzed. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Contribution of HMOs to the weaning gut microbiome maturation
Evaluating utilization of HMOs by the gut microbiota during weaning is expected to inform the importance of HMOs in the selection and the fitness of specific gut bacteria that expand or colonize the infant gut during the different weaning stages.
Measured: From enrollment until late weaning (3-7 month)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Jun 2025
- Study start17 Aug 2022
- Primary completion29 Jan 2024
- Study completion29 Jan 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Study Focus: Weaning Gut MicrobiotaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 18 participants (actual)
Sponsor and investigators
- Lead sponsor
- Technical University of Denmark
- Sponsor type
- University, hospital or other
- Collaborators
- Copenhagen University Hospital at Herlev
- Responsible party
- Principal investigator, Maher Abou Hachem, Technical University of Denmark
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07026526
- Sponsor's protocol ID
- Milkomecohort2025
- Other IDs
- RP2 grant/1026-00386B
- Acronym
- Milkome
- Status last verified
- Mar 2025
- First submitted
- 10 Jun 2025
- Last updated
- 18 Jun 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Jun 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Human Milk Oligosaccharides' Impact on Maturation of the Gut Microbiota
- ClinicalTrials.gov ID
- NCT07026526
- Acronym / sponsor ID
- Milkome / Milkomecohort2025
- Conditions
- Study Focus: Weaning Gut Microbiota
- Keywords
- Early life gut microbiome, Human milk oligosaccharides, mother's milk, weaning
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 18 participants (actual)
- Lead sponsor
- Technical University of DenmarkUniversity, hospital or other
- Collaborators
- Copenhagen University Hospital at Herlev
- Study start
- 17 Aug 2022 (actual)
- Primary completion
- 29 Jan 2024 (actual)
- Study completion
- 29 Jan 2024 (actual)
- First posted
- 18 Jun 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Human milk oligosaccharides (HMOs) are the third largest component of human milk after fat and milk sugar (lactose). HMOs play an important role in selecting the gut microbiota (GM) in newborn breastfed infants. However, the mechanisms underpinning the maturation process that the gut microbiota undergoes during the transition from a breast milk to a solid food diet (weaning) and the impact of HMOs on this transition remain unknown.
The aim of the present study:
- Evaluate the contribution of HMOs to the maturation of the GM during weaning
- Analyze the utilization of HMOs and other complex carbohydrates from diet and from the human host by the GM during the weaning period
We have recruited a cohort of healthy volunteer mothers and their infants (n=9 pairs, two were disqualified and 7 pairs were included in the final analyses). After oral and written informed consent, we collected stool samples from the mother-infant dyads at three time points: 1) just before the introduction of solid food (weaning start), 2) At a time point corresponding to 70% of the infant's meals being breast milk and 30% being toddler food within a 24-hour period (early weaning), and 3) late weaning, defined as the time point corresponding to approx. 30% and 70% of an infant's meals are breast milk and solid food, respectively, within a 24-hour period (late weaning).
The samples have been collected and stored in a Pseudoanonymous Research Bank at the Technical University of Denmark until the data have been analyzed and published, except for participants who allow storage indefinitely through a separate written consent form. In this case, excess material left over after the experiment will be transferred to a Pseudoanonymous Biobank for future research.
The stool samples have been analyzed for gut microbiota composition and carbohydrate utilization potential (based on whole metagenome sequencing). The fecal samples were also enriched on different carbohydrate sources and the enriched consortia were sequenced and analyzed as above. Strains were also isolated from both mother and infant samples via growth on a variety of carbohydrate sources. The genome analyses were performed exclusively on bacteria and human DNA was excluded.
In addition, selected fecal samples were used to colonize germfree mice and the mice were fed with alternating customized mother's milk-like and dietary fiber-rich diets. Similar metagenome analyses were performed on selected fecal samples from this mouse intervention study.
Detailed description
Recruitment of study cohort and informed consent The mother-infants pair cohort have been recruited by Assoc. Prof. Lise Aunsholt (Copenhagen University Hospital, Rigshospitalet, Dept. Neonatology, Copenhagen, Denmark). We have advertised the study at the clinics of general practitioners in the Copenhagen area aiming to recruit pairs during the planned vaccination visit at an infant age of 3 month. Additionally, we have advertised the study via state employed health workers in conjunction with their standard visit at the mothers' residence 8 weeks after birth. The first contact with the subjects has been made either by the visiting nurses or the nurses of the general practitioner clinics.
Eligible participants were healthy mother-infant dyads, who met the inclusion criteria. Two enrolled pairs were disqualified due to intake of either formula or solid food during the study. Two mothers who had antibiotic at birth, otherwise fulfilled the inclusion criteria for both the mother and the infant, were enrolled towards the end of the study due to the low number of recruited volunteers. To assess eligibility, volunteers have answered a questionnaire provided in both English and Danish. For eligible volunteers, a personal meeting was arranged with the mothers and other accompanying persons (e.g. spouses or family members) to brief them on the study at Rigshospitalet Neonate Dept. The meeting was carried out by a nurse assigned by Assoc. Prof. Lise Aunsholt in a meeting room booked for this purpose at Rigshospitalet or online if that is more convenient for the volunteers. The assigned nurse provided oral information covering the purpose of the research, the scope of volunteer participation and general information regarding practicalities related to sample collection and sample handling. The nurse also reiterated the terms of participating in the study, especially its strictly voluntary nature and the rights to withdraw the consent to participate at any time without justification or consequences. The volunteers also got this information in a written form that includes the study purpose and background, the fate of their samples and the informed consent (available in Danish and English, provided as a separate participant information document) for signature. Additionally, the volunteers will also be informed on the possibility of signing separate consents to store their pseudonymized samples for potential future research.
A consideration time of 24-48 hours between the information meeting and the collection of the signed informed consents for both mothers and infants. After volunteers have given their consent, they were enrolled and provided with a study package containing written information regarding sample collection and handling, a feces collection kit, mother's milk collection tube, latex gloves and the study dairy. The stool and milk sample containers will be pre-labelled pseudonymously as to preclude traceability of samples to specific participants.
Sample collection and pseudonymization set-up The mothers were explicitly and thoroughly informed on the timing of the samples and were advised on how to estimate the timing for sample collection. The compliance of the mothers will be evaluated by including a table in the pseudonymous diary, where the mothers were asked to fill the numbers of breastmilk meals and the numbers of solid food means for the last ten meals prior to data collection.
Mothers in the enrolled infant-mother cohort were asked to collect stool and fill out the study diary at the time points indicated in the sampling scheme. The diary was also be pseudonymous to hinder traceability to specific donors. To ensure rapid collection and best quality samples, a person from the Technical University of Denmark (DTU), who is not affiliated with this study, was assigned sample pick-up from a collection site indicated by the mother subjects within the Copenhagen area. The sample collection containers will be pre-labelled with a QR code (generated at DTU) that encodes a letter identifier assigned to each mother-infant pair. In addition, the sample collection containers were pre-labelled with Arabic numerals (1, 2 or 3) to designate the sampling occasion as well as with the codes MF and IF, to designate mother's feces and infant feces, respectively.
Only the collaboration partner at Rigshospitalet and not the DTU team has access to the actual identities of the participants. By contrast, the Rigshospitalet partner did not have the code for the QR labels and will distribute the packages randomly, i.e. with no knowledge of which specific package is handed to which subject. After arrival of samples at DTU, the principle investigator Prof. Maher Abou Hachem will decode the samples and assign the samples to the one letter identifiers of individual mother-infant pairs before the PhD student (who is not involved in sample pick up) processes and handles the samples according to the single letter identifier. Thus, tracking a sample to a specific subject will be virtually impossible for participants in the project.
For the collection of fresh stool samples, participants were supplied and instructed to use a commercially available anaerobic stool collection kit (GutAlive or similar, see participant information document). The mothers will collect their samples after their first bowel movement of a day within the indicated time period. Thereafter mothers will collect their own milk sample and contact the research staff responsible for pick-up of their stool and milk samples. This will minimise the time between sample collection and processing.
Mothers also collected their infant feces from the first bowel movement of either the same day or at the closest occasion where this takes place. As soon as this sample is available, the mother's call for sample pick-up as described above. Until pick-up, mothers were asked to store the mother and infant stool samples in provided insulating cooler boxes.
Functional studies of the microbiota To investigate the potential role of HMOs in the maturation of the infant gut microbiota during weaning, standardized approaches to isolate bacteria from mother's milk and from the mother's/child's faeces, bacterial growth and competition assays, recombinant production and characterization of key proteins as well as analyses of bacterial metabolites of and genetic material (metagenomics and metatranscriptomic shotgun sequencing) will be carried out.
Statistic considerations The study is designed to investigate functional aspects of the microbiota and will focus on within-subject differences, whereby each individual serve as its own control. The number of subjects is within the budgetary constraints of the project and is designed to give the first snapshot into possible subject to subject variations in HMO responsive taxonomic groups and functional pathways.
Risks, side-effects and short and long-term effects The project does not involve any medical procedures on the subjects therefore no risks or other adverse effects are expected for participants.
Biological sample usage and storage The samples will be used for isolation of bacterial strains that are able to grow on HMOs and other complex glycans. Both DNA and RNA will be prepared from the samples and metagenome as well as metatranscriptome analyses will be performed for comparison of microbiota changes over the weaning period. A select of bacterial isolates will be sequenced and their carbohydrate fermentation products analysed.
The pseudonymously pre-labelled faecal material will be stored in a project pseudonymous research sample bank at DTU, Department of Biomedicine and Biotechnology under full compliance with the General Data Protection Regulation and the Danish Data Protection Act based on informed consent by the study volunteers. A data management plan of the project is already prepared for secure storage of data. Similarly, single strain isolates will be stored in a project strain and sample collection research sample bank. The aim of the default storage included in the informed consent is to address potential peer review requests when the study is sent for publications. The faecal and milk biosamples from the cohort will be stored until August 31st 2026 to insure that the material is available for the purposes of peer review requirement of the publications from the study, e.g. in case additional repeated experiments are needed. Thereafter any remaining biomaterial will be transferred to a biobank for future research for volunteers who have consented to this in a separate informed consent form.
Ethical aspects and handling of private data Samples will be pseudonymized and no personal data were accessible for analysis, which will render the data not traceable to a specific participant. The metagenomics and metatranscriptomic analyses will only include microbial DNA/RNA, i.e. Host genetic material information will be neither processed nor analysed.
Project economy The principal investigator Maher Abou Hachem has taken initiative to the study, which is funded by DFF | FNU. The funding provided salaries for a PhD and a postdoc that are employed full-time on the project as well as part-time technical laboratory assistant at DTU and operational costs at the PI's and co-applicants' laboratories. The Institution of the PI (DTU) administers the grant. The PI has no relationship to the funding council nor any other competing interests.
Study Participant compensation Participation in the study was on a voluntary basis and no compensation was offered. The study only involved taking fecal and did not involve any direct medical procedures on the participants. Therefore, no risk of damage was foreseen.
Dissemination of the study results The data as well as the positive, negative and inconclusive results from the study will be published in international peer reviewed journals, presented in scientific conferences and meetings and communicated through popular science fora and news outlets.
Scientific outcomes Insight from the study on the maturation of a healthy microbiota is important for future interventions to avoid the maturation of an aberrant gut community and the implications of this in terms of potential poor health trajectories.
Justification for the necessary involvement of subjects without legal capacity (infants) The aim of the research project is to understand how the maturation of the gut microbiota of infants is affected by human milk oligosaccharides from mothers' milk. Therefore, the research study was only meaningful on infants in the period just before weaning starts until the dietary transition to mostly solid food. The crucial involvement of infants in this specific nutritional phase was not possible to substitute by another target group. The healthy maturation of the gut microbiota of infants during the transition from mother's milk to solid food is critical for a life-long trajectory of health. The study only involves collection of faecal samples from the diapers and does not involve any direct procedure on the infants. Therefore, there are no foreseen risks, pain or any other discomfort incurred on the infant subjects. An informed consent will be collected and signed by both parents or legal guardians. The collaboration partner in Rigshospital Neonatology department, Assoc. Prof. Lise Aunshold is highly qualified and experienced in this type of clinical studies and she will arrange the information to the parents, as infants of this age are not within reach for information.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Mother-infant dyad | – | –The gut microbiome of the cohort, consisting of mother-infant dyads will be analyzed. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Residents of the greater Copenhagen area, Denmark.
Key inclusion criteria (12 listed)
- 1. Mothers
- Age 18 years or older
- Non-smoker
- Residents of the greater Copenhagen area
- Danish or English speaking
Key exclusion criteria (5 listed)
- Mother Use of antibiotics after the 6th month of the last pregnancy
- Infant
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Contribution of HMOs to the weaning gut microbiome maturation
Time frame: From enrollment until late weaning (3-7 month)
Evaluating utilization of HMOs by the gut microbiota during weaning is expected to inform the importance of HMOs in the selection and the fitness of specific gut bacteria that expand or colonize the infant gut during the different weaning stages.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Jun 2025.
- Individual participant dataSharing planned: No
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Study Focus: Weaning Gut Microbiota, run by Technical University of Denmark at 1 site in Denmark.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 12 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 Jun 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Contribution of HMOs to the weaning gut microbiome maturation (time frame: From enrollment until late weaning (3-7 month)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Jun 2025.